Henderson Michael Thomas
- SEC CIK
- 0001779990
In the past year, 13 open-market sale filings worth $36.3M and no purchases.
Current role at each company
- APGE Apogee Therapeutics, Inc.Chief Executive Officeras of Sep 3, 2026
- SYRE Spyre Therapeutics, Inc.Directoras of Jun 23, 2026
- ARYD ARYA Sciences Acquisition Corp IVDirectoras of Jul 31, 2024
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $36.3M
- 13 filings
- Net
- −$36.3M
- Bought minus sold
- Companies
- 2
- With open-market trades
Trades
Every Form 4 that lists Henderson Michael Thomas as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
APGE Apogee Therapeutics, Inc.
Chief Executive Officer20 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 5, 2024 (view filing) | Jul 5 | Same day | Henderson Michael ThomasChief Executive Officer | SSale | −15.0K | $37.26 | −$558.9K | −1.0%1.47M after | 10b5-1 |
| Aug 9, 2024 (view filing) | Aug 7 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −40.0K | $40.62 | −$1.62M | −2.7%1.43M after | 3 lots10b5-1 |
| Sep 6, 2024 (view filing) | Sep 4 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −40.0K | $47.62 | −$1.90M | −2.8%1.39M after | 2 lots10b5-1 |
| Oct 4, 2024 (view filing) | Oct 2 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −40.0K | $56.23 | −$2.25M | −2.9%1.35M after | 2 lots10b5-1 |
| Nov 8, 2024 (view filing) | Nov 6 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −15.0K | $59.22 | −$888.3K | −1.1%1.34M after | 2 lots10b5-1 |
| Dec 6, 2024 (view filing) | Dec 4 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −15.0K | $46.58 | −$698.7K | −1.1%1.32M after | 2 lots10b5-1 |
| Jan 10, 2025 (view filing) | Jan 8 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −15.0K | $48.85 | −$732.7K | −1.1%1.31M after | 2 lots10b5-1 |
| Feb 7, 2025 (view filing) | Feb 5 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −15.0K | $40.58 | −$608.7K | −1.1%1.30M after | 10b5-1 |
| Mar 7, 2025 (view filing) | Mar 5 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −10.0K | $30.15 | −$301.5K | −0.8%1.29M after | 2 lots10b5-1 |
| Nov 13, 2025 (view filing) | Nov 13 | Same day | Henderson Michael ThomasChief Executive Officer | SSale | −20.0K | $63.01 | −$1.26M | −1.5%1.27M after | 4 lots10b5-1 |
SYRE Spyre Therapeutics, Inc.
Director2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 8, 2026 (view filing) | May 8 | Same day | Henderson Michael ThomasDirector | SSale | −80.0K | $74.40 | −$5.95M | −47.4%88.6K after | 4 lots10b5-1 |
| Jun 23, 2026 (view filing) | Jun 22 | 1 day | Henderson Michael ThomasDirector | SSale | −20.0K | $100.00 | −$2.00M | −22.6%68.6K after | 10b5-1 |